What is Akesis?
Akesis operates at the intersection of advanced engineering and clinical oncology, focusing on the development of sophisticated stereotactic radiosurgery and linear accelerator platforms. By leveraging patented, continuous 360-degree rotational technology integrated with real-time, in-line imaging, the company aims to redefine the standards of precision in radiation therapy. Headquartered near San Francisco, California, Akesis maintains a domestic manufacturing footprint, ensuring rigorous quality control as it advances its flagship Galaxy RTi and Gemini360 systems toward commercial readiness. The company's mission is rooted in democratizing access to life-saving radiation medicine through technological evolution.
How much funding has Akesis raised?
Akesis has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Akesis
PPP
Public-Private Partnership
What's next for Akesis?
With the recent influx of capital, Akesis is well-positioned to transition from the research and development phase toward broader clinical validation and eventual market entry. The strategic focus will likely center on finalizing the regulatory pathways for its core product suite and scaling manufacturing capabilities to meet anticipated demand in the oncology equipment market. As the company moves deeper into its late-stage lifecycle, the emphasis will shift toward establishing clinical partnerships and demonstrating the efficacy of its continuous rotational technology in real-world settings. This growth phase is critical for Akesis as it seeks to disrupt the established landscape of radiation medicine with its high-precision, imaging-integrated solutions.
See full Akesis company page
